- Published on
Emergency and Acute Medicine – Drug Withdrawal
Drug Withdrawal refers to the constellation of symptoms that occur when a substance that has been used chronically is abruptly reduced or discontinued. The hallmark of many withdrawal syndromes—particularly those involving benzodiazepines, barbiturates, and opioids—is neuroexcitation, resulting from adaptive changes in the central nervous system. While withdrawal from sedative-hypnotics such as benzodiazepines and barbiturates can be life-threatening, opioid withdrawal is typically not fatal but can be extremely uncomfortable. Withdrawal from stimulants such as cocaine and amphetamines is also generally not life-threatening but can cause significant psychological distress.
The pathophysiology involves neuroadaptation to chronic drug exposure. With prolonged use, the body adjusts to the presence of the substance, leading to tolerance, where increasing doses are needed to achieve the same effect. When the drug is removed, these adaptations persist, resulting in withdrawal symptoms. It is important to distinguish tolerance from withdrawal, as they are related but separate phenomena.
Clinical features vary depending on the substance. Benzodiazepine and barbiturate withdrawal presents with anxiety, agitation, tremor, insomnia, tachycardia, hypertension, hyperthermia, and autonomic instability, with the potential for seizures and life-threatening complications. Opioid withdrawal is characterized by restlessness, irritability, drug craving, yawning, piloerection (“goosebumps”), mydriasis, nausea, vomiting, diarrhea, abdominal pain, tachycardia, and hypertension. Cocaine withdrawal typically manifests with depressed mood, fatigue, vivid dreams, sleep disturbances, and psychomotor changes, while amphetamine withdrawal presents with fatigue, irritability, anxiety, and sleep disturbances.
Diagnosis is primarily clinical and relies on a detailed substance use history, including the type of drug, time of last use, and any previous withdrawal episodes. Physical examination focuses on vital signs and signs of autonomic instability. Laboratory testing (electrolytes, renal function, glucose, CBC) may be helpful to identify complications or alternative diagnoses, although urine drug screening rarely changes acute management. Imaging is reserved for cases where the diagnosis is unclear or other pathology is suspected.
Management begins with initial stabilization, including airway, breathing, and circulation, IV access, fluid resuscitation, and monitoring. Treatment is then tailored to the specific withdrawal syndrome. For benzodiazepine or barbiturate withdrawal, aggressive supportive care and substitution with a long-acting agent of the same class are recommended, using medications such as Diazepam (5–10 mg IV repeated as needed; 5–20 mg PO for mild symptoms) or Lorazepam (1–2 mg PO or 2 mg IV repeated as needed). Severe cases or seizures may require Phenobarbital (15–20 mg/kg IV).
In opioid withdrawal, treatment is largely supportive. Symptom control includes antiemetics such as Ondansetron (4–8 mg PO/IV) and autonomic symptom relief with Clonidine (0.1–0.3 mg PO every 4–6 hours). Opioid replacement therapy may be considered in certain cases, especially when withdrawal complicates other medical conditions. For cocaine and amphetamine withdrawal, management is supportive, focusing on rest, hydration, and monitoring for psychiatric symptoms.
Disposition depends on severity and associated risks. Patients with moderate-to-severe symptoms, persistent withdrawal, psychosis, autonomic instability, or significant comorbid conditions require admission. Those with mild symptoms who respond to therapy and are psychiatrically stable may be discharged with appropriate follow-up. Referral to a detoxification or rehabilitation program is essential for long-term management.
A key clinical pearl is to avoid misdiagnosing other serious medical conditions as withdrawal, as infections, metabolic disturbances, or intracranial pathology may mimic withdrawal syndromes. Additionally, clinicians should ensure adequate dosing of benzodiazepines in sedative withdrawal, as under-treatment can lead to severe complications, including seizures.
0 Comments
